In a report released yesterday, Julian Harrison from BTIG maintained a Buy rating on Aerovate Therapeutics (AVTE – Research Report), with a price target of $24.00. The company’s shares closed last Wednesday at $17.94.
According to TipRanks.com, Harrison is ranked 0 out of 5 stars with an average return of -18.4% and a 31.3% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, Prometheus Biosciences, and United Therapeutics.
Aerovate Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $24.00.
The company has a one-year high of $29.43 and a one-year low of $7.74. Currently, Aerovate Therapeutics has an average volume of 46.34K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. Its initial focus is on advancing AV-101, dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, a devastating disease impacting people in the United States and Europe.
Read More on AVTE:
- PPL (PPL) Gets a Hold Rating from Mizuho Securities
- Fulcrum Therapeutics (FULC) Gets a Buy Rating from Leerink Partners
- Zurn Water Solutions (ZWS) Gets a Buy Rating from Oppenheimer
- Crinetics Pharmaceuticals (CRNX) Gets a Buy Rating from JMP Securities
- Trulieve Cannabis (TCNNF) Receives a Buy from BTIG